Vanguard Global Advisers
DTIL icon

Vanguard Global Advisers’s Precision BioSciences DTIL Stock Holding History

Vanguard Global Advisers’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.5K Hold
10,881
– – ﹤0.01% 2844
2026
Q1 		$59.8K Buy
+10,881
New +$50.2K ﹤0.01% 2941

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Vanguard Global Advisers's DTIL Position: Q2 2026 in Review

Vanguard Global Advisers held its Precision BioSciences (DTIL) position steady in Q2 2026 at 10,881 shares worth $85.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2844.

Vanguard Global Advisers first reported a position in DTIL in Q1 2026 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Vanguard Global Advisers held 10,881 shares of Precision BioSciences worth $85.5K as of Q2 2026.
  • Vanguard Global Advisers left its Precision BioSciences share count unchanged in Q2 2026.
  • Precision BioSciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2844 holding.
  • Vanguard Global Advisers first reported a position in Precision BioSciences in Q1 2026 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.